34176-17-5

Usage

Preparation

Preparation by reaction of benzyl halide with 2,4,5-tri-hydroxyacetophenone in the presence of potassium carbonate in refluxing acetone (62%).

Upstream product

• 29682-12-0 1-[4-(benzyloxy)-2-hydroxyphenyl]ethanone 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 1818-27-5 1-(2,4,5-trihydroxyphenyl)ethanone 
• 1818-28-6 2',4',5'-trimethoxyacetophenone 
• 7298-21-7 1-(2,4-dihydroxy-5-methoxyphenyl)ethan-1-one 
• 34176-18-6 1-(4-(benzyloxy)-2-hydroxy-5-methoxyphenyl)ethan-1-one 

Downstream Products

• 34176-18-6 1-(4-(benzyloxy)-2-hydroxy-5-methoxyphenyl)ethan-1-one 
• 7298-39-7 4',5'-bis(benzyloxy)-2'-hydroxyacetophenone 
• 82298-12-2 2'-Hydroxy-3,4'-dibenzyloxy-4,5'-dimethoxychalkone 
• 209982-68-3 7-Benzyloxy-2-(3-benzyloxy-4-methoxy-phenyl)-3-hydroxy-6-methoxy-chromen-4-one 
• 209982-69-4 7-Benzyloxy-2-(3-benzyloxy-4-methoxy-phenyl)-3,6-dimethoxy-chromen-4-one 
• 58511-89-0 6,7-dimethoxy-4H-benzopyran-4-one 
• 74693-70-2 2'-hydroxy-4',5'-dibenzyloxy-3,4-dimethoxychalkone 
• 74693-71-3 2',4',5'-tribenzyloxy-3,4-dimethoxychalkone 
• 74693-72-4 2',4',5'-tribenzyloxy-3,4-dimethoxychalkone epoxide 
• 7298-21-7 1-(2,4-dihydroxy-5-methoxyphenyl)ethan-1-one 

Relevant academic research and scientific papers

Structure Optimization of Gatastatin for the Development of γ-Tubulin-Specific Inhibitor

Gatastatin (O7-benzyl glaziovianin A) is a γ-tubulin-specific inhibitor that is used to investigate γ-tubulin function in cells. We have previously reported that the unsubstituted phenyl ring of the O7-benzyl group in gatastatin is important for γ-tubulin

γ-TUBULIN INHIBITOR

To provide a novel compound with a microtubule polymerization inhibitory activity promising as an anticancer agent.SOLUTION: The invention provides a compound represented by formula (I) in the figure or a pharmaceutically acceptable salt thereof.

2-OXO-5H-CHROMENO[4,3-B]PYRIDINES FOR USE IN THE TREATMENT OF HEPATITIS B

The present invention discloses compounds according to Formula (I), wherein R1, R2a, R2b, R3, R4, and R5 are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving hepatitis B by administering the compound of the invention.

Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease

PCT No. PCT/KR97/00144 Sec. 371 Date Jan. 14, 1999 Sec. 102(e) Date Jan. 14, 1999 PCT Filed Jul. 25, 1997 PCT Pub. No. WO98/04541 PCT Pub. Date Feb. 5, 1998The present invention relates to novel flavone/flavanone compounds or their pharmaceutically acceptable salts and process for preparation thereof for protecting gastrointestinal tracts against gastritis, ulcers and inflammatory bowel disease.

Structure-activity requirements for flavone cytotoxicity and binding to tubulin

A series of 79 flavones related to centaureidin (3,6,4'-trimethoxy- 5,7,3'-trihydroxyflavone, 1) was screened for cytotoxicity in the NCI in vitro 60-cell line human tumor screen. The resulting cytotoxicity profiles of these flavones were compared for deg

Structural Elucidation of Two New Chromones Isolated from Glasswort (Salicornia europaea L.)

Two chromones isolated from the methanol extract of glasswort (Salicornia europaea L.) were elucidated to be 7-hydroxy-6-methoxychromone and 7-O-β-D-glucopyranosyl-6-methoxychromone on the basis of chemical and spectral analyses and synthetic studies.These two are natural products hitherto unknown.